Dicerna Pharmaceuticals
Earnings Date & Report
Last updated:
Dicerna Pharmaceuticals’s last earnings date was on 9 Nov 2021. It reported its quarterly earnings per share (EPS) reaching -$0.22, beating the estimated value of -$0.41 by $0.19. The company’s quarterly earnings increased by 28.81% to 62.95M US dollars compared to the same quarter of the previous year. Over the last year, Dicerna Pharmaceuticals’s earnings per share have grown by 24.14%.
Dicerna Pharmaceuticals stock Earnings report, Estimates & History
| 2017-03-30 | -0.73 | -0.68 |
|---|---|---|
| 2017-05-08 | -0.7 | -0.68 |
| 2017-08-10 | -0.6 | -1.15 |
| 2017-11-02 | -0.69 | -0.92 |
| 2018-03-08 | -0.77 | -0.9 |
| 2018-05-14 | -0.38 | -0.3 |
| 2018-08-08 | -0.42 | -0.68 |
| 2018-11-05 | -0.25 | -0.35 |
| 2019-03-11 | -0.22 | -0.29 |
| 2019-05-09 | -0.22 | -0.38 |
| 2019-08-08 | -0.31 | -0.35 |
| 2019-11-07 | -0.28 | -0.45 |
| 2020-02-27 | 0.56 | -0.58 |
| 2020-05-07 | 0.27 | -0.31 |
| 2020-08-06 | 0.1 | -0.43 |
| 2020-11-05 | -0.2 | -0.29 |
| 2021-02-25 | -0.03 | -0.49 |
| 2021-05-06 | -0.37 | -0.39 |
| 2021-08-09 | 0.51 | -0.53 |
| 2021-11-09 | -0.41 | -0.22 |
Estimated - a value of Apple’s earnings per share estimated by analysts based on its past and current financial statements.
Reported - a real value of Apple’s earnings per share reported by the company.
Dicerna Pharmaceuticals stock earnings history by quarter
| Date | Estimated EPS | Reported EPS | Estimated revenue | Actual revenue | Earnings call | |
|---|---|---|---|---|---|---|
| 9 Nov 2021 | Beat | -$0.41 | -$0.22 | 43.78M | 62.95M | Earnings Call Transcript |
| 9 Aug 2021 | Missed | $0.51 | -$0.53 | 91.29M | 41.33M | Earnings Call Transcript |
| 6 May 2021 | Missed | -$0.37 | -$0.39 | 46.52M | 47.60M | |
| 25 Feb 2021 | Missed | -$0.03 | -$0.49 | 67.25M | 40.95M | Earnings Call Transcript |
| 5 Nov 2020 | Missed | -$0.2 | -$0.29 | 33.70M | 48.87M | |
| 6 Aug 2020 | Missed | $0.1 | -$0.43 | 9.40M | 40.44M | |
| 7 May 2020 | Missed | $0.27 | -$0.31 | 29.63M | 34.02M | |
| 27 Feb 2020 | Missed | $0.56 | -$0.58 | 6.83M | 7.08M | Earnings Call Transcript |
| 7 Nov 2019 | Missed | -$0.28 | -$0.45 | 4.99M | 8.03M | |
| 8 Aug 2019 | Missed | -$0.31 | -$0.35 | 5.03M | 5.68M | Earnings Call Transcript |
| 9 May 2019 | Missed | -$0.22 | -$0.38 | 2.09M | 3.10M | Earnings Call Transcript |
| 11 Mar 2019 | Missed | -$0.22 | -$0.29 | 1.16M | 1.54M | Earnings Call Transcript |
| 5 Nov 2018 | Missed | -$0.25 | -$0.35 | 1.10M | 1.54M | Earnings Call Transcript |
| 8 Aug 2018 | Missed | -$0.42 | -$0.68 | 1.90M | 1.54M | Earnings Call Transcript |
| 14 May 2018 | Beat | -$0.38 | -$0.3 | 1.95M | 1.54M | Earnings Call Transcript |
| 8 Mar 2018 | Missed | -$0.77 | -$0.9 | 1.21M | 1.41M | Earnings Call Transcript |
| 2 Nov 2017 | Missed | -$0.69 | -$0.92 | 355.5K | 474K | |
| 10 Aug 2017 | Missed | -$0.6 | -$1.15 | 175.41K | 252K | Earnings Call Transcript |
| 8 May 2017 | Beat | -$0.7 | -$0.68 | 136.91K | 133K | Earnings Call Transcript |
| 30 Mar 2017 | Beat | -$0.73 | -$0.68 | 142.77K | 133K | Earnings Call Transcript |
Dicerna Pharmaceuticals Earnings report FAQs
When is Dicerna Pharmaceuticals's next Earnings date?
The company has not set the next earnings date yet. The latest Dicerna Pharmaceuticals's earnings date was on 5 Nov 2020.
What are earnings?
Earnings are the net income of a company after all taxes and expenses have been deducted. They are the main figure for determining the price of a company's shares.
What does EPS stand for?
EPS stands for earnings per share, which is the basic measure of a company's earnings. It indicates how much money each share earned for the company.
How to calculate earnings per share?
Earnings per share (EPS) can be calculated by dividing a company's net income by the number of common shares outstanding. If the company pays preferred dividends, they are first subtracted from the company’s net income.
Formula:
What is earnings per share estimate?
Earnings estimate is analysts’ prediction of a company’s earnings value in the next quarter or fiscal year based on past and current financial statements of a company. It is an important indicator for both current and future investors.